NCT07003386View on ClinicalTrials.gov

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 14, 2028

Study Completion Date

September 30, 2028

Conditions
Acute Ischemic Stroke AIS
Interventions
DRUG

Galantamine

Start within 24 hours of hospitalization, administer 5.0 mg of galantamine via intramuscular injection once daily, and continue the treatment for 10 days.

DRUG

Standard treatment for acute ischemic stroke

Standard treatment for acute ischemic stroke

Trial Locations (1)

200080

RECRUITING

Shanghai Yueyang Integrated Medicine Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Yueyang Integrated Medicine Hospital

OTHER

NCT07003386 - Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke | Biotech Hunter | Biotech Hunter